Allarity Therapeutics Publishes Interim Report for the Period January – June 2021
23. August 2021 01:00 ET
|
Allarity Therapeutics A/S
Press ReleaseHørsholm, Denmark (August 23, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announces the publication of its Interim Report for the period January – June 2021. The...
New Publication Date for Allarity Therapeutics’ Q2 2021 Interim Report
19. August 2021 15:45 ET
|
Allarity Therapeutics A/S
Press ReleaseHørsholm, Denmark (August 19, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced a new publication date for the Company’s Q2 2021 Interim Report, which is now...
Allarity Therapeutics Elaborates on the Contents of the Meeting Agenda for the Extraordinary General Meeting Announced on August 16, 2021
18. August 2021 02:26 ET
|
Allarity Therapeutics A/S
Press Release Hørsholm, Denmark (August 18, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) yesterday published a notice to convene an Extraordinary General Meeting on August 31,...
NOTICE OF EXTRAORDINARY GENERAL MEETING
16. August 2021 17:18 ET
|
Allarity Therapeutics A/S
16 August 2021 ALLARITY THERAPEUTICS A/S31 AUGUST 2021 AT 13:00 (CET) The Board of Directors hereby convenes an Extraordinary General Meeting of Allarity Therapeutics A/S, company registration...
Allarity Therapeutics’ oral PARP inhibitor, Stenoparib, demonstrates additional pre-clinical antiviral activity against new variants of Coronavirus
05. August 2021 07:00 ET
|
Allarity Therapeutics A/S
Current positive results with 3 variants, including alpha variant B.1.1.7 (“British” variant), beta variant B.1351 (“South African” variant) and gamma variant P.1 (“Brazilian” variant), follows...
Allarity Therapeutics and Lantern Pharma Enter into Agreement for Future Clinical Development of Irofulven
26. Juli 2021 02:30 ET
|
Allarity Therapeutics A/S
Lantern will reacquire global rights to Irofulven and assume full authority to manage and guide future clinical and commercial development of the program Press release Hørsholm, Denmark and...
Allarity Therapeutics Issues Share Units as Payment-In-Kind for Services Rendered During Rights Issue in Q2 2021
14. Juli 2021 11:00 ET
|
Allarity Therapeutics A/S
Issuance of share Units fullfils payment obligations to guarantors and coordinator/bookrunner of Rights Issue conducted in Q2 2021 Press release Hørsholm, Denmark (14 July 2021) Allarity...
Allarity Therapeutics Receives Acceptance & Review Notification from U.S. FDA for Pre-Market Approval Application for Dovitinib-DRP®
05. Juli 2021 14:00 ET
|
Allarity Therapeutics A/S
Administrative acceptance review notification of pre-market approval (PMA) application is first step in multi-step process conducted by the FDAThe PMA is submitted in support of an imminent new drug...
Last day of trading with Allarity Therapeutics A/S BTU
24. Juni 2021 10:05 ET
|
Allarity Therapeutics A/S
Press release Hørsholm, Denmark (24 June 2021) – Allarity Therapeutics A/S (“Allarity”) today announced that the recently completed Rights Issue, announced on 10 June 2021, has now been registered...
Allarity Therapeutics and Oncoheroes Biosciences to Partner on Pediatric Cancer Development of Dovitinib and Stenoparib
14. Juni 2021 07:00 ET
|
Allarity Therapeutics A/S
Oncoheroes will fund and advance clinical development of both dovitinib and stenoparib in pediatric cancersAllarity is preparing to file a first U.S. new drug application (NDA) for the approval...